Piśmiennictwo:
 
1. Jakub Gołąb, Marek Jakóbisiak, Witold Lasek, Tomasz Stokłosa, Immunologia. PWN, Warszawa 2012,
2. T. Jock Murray The history of multiple sclerosis: the changing frame of the disease over the centuries. Journal of the Neurological Sciences 277, S1 (2009) S3 S8.
3. Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2:1063 6.
4. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellulardomain of the myelin oligodendrocyte glycoprotein. Brain 1999; 122:2089–100.
5. Bielekova B, Sung M-H, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high avidity myelin specific CD4+ T cells in multiple sclerosis. J Immunol 2004; 172:3893–904.
6. Martin Roland Hohlfeld,Reinhard, McFarland,H.F. Chapter 53 - Multiple Sclerosis , Neurological Disorders, Jan 2003
7. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56:1628-1636.
8. McDonald, W. I., Compston, A., Edan, G., et al. (2001). Recommended Diagnostic Criteria for Multiple Sclerosis; Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121–127.
9. Jurewicz, A., Biddison, W. E., &Antel, J. P. (1998). MHCclass I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol 160, 3056–3059.
10. Derek Gay, George Dick, Is multiple sclerosis caused by anoral spirochaete? The Lancet, July 12, 1986
11. Beck RW, Cleary PA, Anderson MJ, et al. A randomised controlled trial of corticosteroids in the treatment of acuteopticneuritis. New Engl J Med 1992; 326:581–8.
12. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Trials of maintenan cetreatment with prednisolone and soluble aspirin. Lancet 1961; 1:127 9.
13. Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R., & Edwards, D. R. (1998). Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21, 75– 80.
14. Patten SB, Metz LM: Interferon β-1a and depression in relapsing-remitting multiple sclerosis: ananalysis of depression data from the PRISMS clinicaltrial. MultScler 2001; 7:243-248.
15. Glucocorticosteroidtherapy for multiple sclerosis: A critical review. Peter-Brian Andersson, Donald E. GoodkinJournal of the Neurological Sciences 160 (1998) 16–25.
16. Aharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1997). Copolymer 1 induces T cells of the T helpertype 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc NatlAcadSci USA 94, 10821– 10826.
17. Chen, M., &Dhib-Jalbut, S. (2002). Glatirameracetate (GA)-reactive T cells producebrain-derivedne urotrophic factor (BDNF). MultScler 8(suppl. 1), P328, S123.
18. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocalleuko encephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med2005, 353:369–374.
19. Langer-Gould A, Atlas SW, Bollen AW, Pelletier D: Progressive multifocalleuko encephalopathy in a patient treated with natalizumab. N Engl J Med2005, 353:375–381.
20. Mitoxantrone as rescue therapy in worsening relapsing–remitting MS patients receiving IFN-hJ. Correale et al. / Journal of Neuroimmunology 162 (2005) 173–183.
21. Bellosillo, B., Colomer, D., Pons, G., & Gil, J. (1998). Mitoxantrone, a topoisomerase II inhibitor, inducesapoptosis of B-chroniclymphocyticleukaemiacells. Br J Haematol 100, 142– 146.
22. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345:747–55.
23. NaokoNiimi, KunikoKohyama, Shintaro Kamei2 and Yoh Matsumoto. Intravenous immunoglobulin therapy prevents development of autoimmune encephalomyelitis and suppresses activation of matrix metallo proteinases. Neuropathology 2011; 31, 392–400.
24. Timothy Vollmer, Lyndon Key, ValerieDurkalski, William Tyor, John Corboy, Silva Markovic-Plese, Jana Preiningerova, Marco Rizzo, Inderjit Singh.  Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607–08
25. Oliver Neuhaus, Olaf Stüve, Scott S Zamvil, and Hans-Peter Hartung. Arestatins a treatment option for multiple sclerosis? Lancet Neurol2004; 3: 369–71.
26. Lin Xie, Xiao-Kang Li, ShiroTakahara. Curcumin has bright prospects for the treatment of multiple sclerosis. International Immunopharmacology 11 (2011) 323–330.
27. Kjell-Morten Mohr. Vitamin D treatment in multiple sclerosis. Journal of the Neurological Sciences 286 (2009) 104–108
28. Jacek Losy, Alicja Kalinowska-Łyszczarz. Emerging disease-modifying oral therapies for multiple sclerosis. Journal of Neuroimmunology 231 (2011) 15–22.
29. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004;55:756.
30. KazemMousavizadeh, Ahmad Reza Dehpour, AlirezaMinagar and PedramGhafourifar. Uric acid: a novel treatment strategy for multiple sclerosis. TRENDS in Pharmacological Sciences Vol.24 No.11 November 2003
31. VolkerBrinkmannFTY720 (fingolimod) in Multiple Sclerosis:therapeutic effects in the immune and the central nervous system. British Journal of Pharmacology (2009), 158, 1173–1182
32. Douglas R. JefferyRecentadvances in treating multiple sclerosis: efficacy, risks and place in therapy. TherAdvChronicDis. 2013 January; 4(1): 45–51.